Gapping up
In reaction to earnings/guidance:
- FIVN +7.9%, AL +7.4%, ZI +6.4%, BCO +5.1%, FI +4.9%, MRO +3.3%, IR +3.3%, M +3.1%, LGIH +2.4%, ARNC +2.3%, RSG +2.2%, BCC +2.2%, NXST +1.6%, EVER +1.5%, PRIM +1.4%, WMB +1.4%, PLOW +1.4%, CDNS +1.2%, BNS +1.2%, GFL +1.1%, CBRE +1.1%, EXR +0.9%
Other news:
- ONCY +14.5% (reports preclinical data demonstrating the synergistic anti-cancer activity of pelareorep combined with car t cell therapy in solid tumors)
- PLX +10.4% (Protalix BioTherapeutics and Chiesi Global Rare Diseases announce "positive" topline results from the BRIGHT Phase III clinical trial evaluating pegunigalsidase alfa, 2 mg/kg, administered every four weeks, for the potential treatment of Fabry disease)
- AMC +6.1% (to reopen all 13 of its NYC theatres on March 5)
- PSN +4.2% (wins contract with the US Postal Service worth up to $600 mln)
- UFPI +2.5% (to acquire operating assets of Spartanburg Forest Products)
- SASR +1.3% (files for mixed securities shelf offering)
- BIP +1.2% (KMI and BIP announce minority interest sale in Natural Gas Pipeline)
Analyst comments:
- SNSS +16.6% (upgraded to Outperform from Perform at Oppenheimer)
- TMST +6.3% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- KOS +5.3% (upgraded to Buy from Neutral at Goldman)
- RSG +2.2% (upgraded to Overweight from Neutral at JP Morgan)
- GTES +1.9% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)